Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1601P - Estimated years of potential life lost due to absence of pembrolizumab in SUS

Date

17 Sep 2020

Session

E-Poster Display

Topics

Bioethical Principles and GCP

Tumour Site

Presenters

Gabriel Lenz

Citation

Annals of Oncology (2020) 31 (suppl_4): S903-S913. 10.1016/annonc/annonc287

Authors

G. Lenz1, R.A. Pellegrini1, L.S. Lago2, P.S. Azevedo3, L.L. Tôrres3, G. Lopes4

Author affiliations

  • 1 Escola De Medicina, Pontifícia Universidade Católica do Rio Grande do Sul, 90610-000 - Porto Alegre/BR
  • 2 Médico Oncologista, Hospital Santa Rita, 90020-090 - Porto Alegre/BR
  • 3 Faculdade De Fármacia, Universidade Federal de Minas Gerais, 31270-901 - Belo Horizonte/BR
  • 4 Sylvester Comprehensive Cancer Center, University of Miami, 33146 - Miami/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1601P

Background

Pembrolizumab, a monoclonal antibody anti-programmed death ligand 1 (PD-1), was approved in October 2017 by National Health Surveillance Agency (ANVISA) for first-line treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥50% based on the KEYNOTE 024 (KN24). In our public health system (SUS), however, it is not approved. Considering that Lung Cancer (LC) is the major cause of cancer mortality in our country, and NSCLC represents more than 85% of the patients (pts), it is notable its huge impact in terms of lives lost, economic and social burden of this disease, and so an estimation of the Years of Potential Life Lost (YPLL) would be an helpful tool to address this topic in oncology medical societies.

Methods

The Number of Eligible Patients (NEP) with NSCLC was taken from our National Cancer Institute (INCA). Pts with life insurance and other histologies, not NSCLC, were disregarded. For the YPLL calculation purpose the NEP between the years 2017 & 2019 was multiply by the difference of the documented improvement in the median overall survival of the therapeutic regimen, 30 months and 14,2 months - KN24 for pembrolizumab and chemotherapy regime respectively. For a conservative calculation, we assume that all eligible pts would have had access at the time of first approval in the country.

Results

INCA estimates 4,703 (October and November 2017); 62,540 (2018 and 2019) new cases of LC/year in Brazil. Of these, 76.3% are treated by SUS, upon which 89% are NSCLC. Of these 44% have metastasis at diagnosis, and 43%, 7%, 6% are diagnosed in stages III, II and I, respectively. It was used a recurrences rate of 53.79% in stage III, 46.49% in II and 26% in I in 5 years from diagnosis, and considering as 17,38% as PD-L1 ≥ 50% (Gelatti et, 2020): resulted in 5,858 NEP from 2017 until 2019, resulting in a loss of approximately 7,713 YPLL in 26 months.

Conclusions

Pembrolizumab improves overall survival outcome compared to chemotherapy in PD-L1 positive (TPS≥50%) naive stage IV NSCLC patients and this represents a substantial gain YPLL. Collaborative initiatives are needed to address this major barrier to access to treatment and relive the economic and social burden of NSCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.